Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Verily
Japan-UK firm is looking to build on a combination of internal and external assets to pursue a more independent business development path in Japan and beyond, in parallel with ongoing discovery and development collaborations.
During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.
The idea seems to stem from thinking that human interaction is the best way to combat rumors and false statements.
Accenture released its Life Sciences Technology Vision 2022 report, including a survey of biopharma execs on trends like synthetic data and quantum computing.
- Implantable Devices
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Glucose Testing
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
- Alphabet Inc.
- Verily Life Sciences LLC